Intravenous Iron Therapy Versus Blood Transfusion for Iron Deficiency Anemia: A Systematic Review

IF 2.5 2区 医学 Q2 HEMATOLOGY
Martin Bedan , Christian Lottrup
{"title":"Intravenous Iron Therapy Versus Blood Transfusion for Iron Deficiency Anemia: A Systematic Review","authors":"Martin Bedan ,&nbsp;Christian Lottrup","doi":"10.1016/j.tmrv.2025.150905","DOIUrl":null,"url":null,"abstract":"<div><div>This systematic review aimed to assess and compare the effect of blood transfusion and intravenous iron therapy on the hemoglobin levels based on clinical trials. To do this, a search was conducted 25<sup>th</sup> of September 2024 by using PubMed, Cochrane, and Embase databases to identify studies comparing intravenous iron with blood transfusion in patients with iron deficiency anemia (&lt;12 g/dL for women and &lt;13 g/dL for men). The outcome selected was change in hemoglobin levels. The quality of the trials was assessed using Cochrane Risk of Bias Tool and Newcastle-Ottawa Quality Assessment Scale. We included 5 studies (three randomized controlled trials, 1 observational study and 1 retrospective study) comprising a total of 154,539 patients. Patient populations were heterogenous, encompassing surgical patients, patients undergoing hip fracture and pregnant women. Due to heterogeneity among the included studies, hemoglobin levels were reported at varying follow-up intervals. At 3 weeks follow-up or later after initial treatment, 3 studies reported significantly higher hemoglobin levels (ranging from 0.7 g/dL to 1.4 g/dL higher) in the intravenous iron group compared to the blood transfusion group. The remaining 2 studies found similar hemoglobin levels. Less than 3 weeks after initial treatment, 2 studies reported significantly higher hemoglobin levels in the blood transfusion group compared to the intravenous iron group. Our findings indicate that blood transfusion is more effective in achieving a rapid increase in hemoglobin levels shortly after therapy initiation, although this effect diminishes relatively swiftly. In contrast, intravenous iron seems to exert a more gradual increase in, but also longer lasting effect on, hemoglobin levels. However, our findings are limited by the small number of trials as well as questionable methodological quality of the included studies, resulting in a high risk of bias. Further investigation is warranted.</div></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"39 3","pages":"Article 150905"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887796325000306","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This systematic review aimed to assess and compare the effect of blood transfusion and intravenous iron therapy on the hemoglobin levels based on clinical trials. To do this, a search was conducted 25th of September 2024 by using PubMed, Cochrane, and Embase databases to identify studies comparing intravenous iron with blood transfusion in patients with iron deficiency anemia (<12 g/dL for women and <13 g/dL for men). The outcome selected was change in hemoglobin levels. The quality of the trials was assessed using Cochrane Risk of Bias Tool and Newcastle-Ottawa Quality Assessment Scale. We included 5 studies (three randomized controlled trials, 1 observational study and 1 retrospective study) comprising a total of 154,539 patients. Patient populations were heterogenous, encompassing surgical patients, patients undergoing hip fracture and pregnant women. Due to heterogeneity among the included studies, hemoglobin levels were reported at varying follow-up intervals. At 3 weeks follow-up or later after initial treatment, 3 studies reported significantly higher hemoglobin levels (ranging from 0.7 g/dL to 1.4 g/dL higher) in the intravenous iron group compared to the blood transfusion group. The remaining 2 studies found similar hemoglobin levels. Less than 3 weeks after initial treatment, 2 studies reported significantly higher hemoglobin levels in the blood transfusion group compared to the intravenous iron group. Our findings indicate that blood transfusion is more effective in achieving a rapid increase in hemoglobin levels shortly after therapy initiation, although this effect diminishes relatively swiftly. In contrast, intravenous iron seems to exert a more gradual increase in, but also longer lasting effect on, hemoglobin levels. However, our findings are limited by the small number of trials as well as questionable methodological quality of the included studies, resulting in a high risk of bias. Further investigation is warranted.
静脉铁治疗与输血治疗缺铁性贫血:一项系统综述
本系统综述旨在评估和比较输血和静脉铁治疗在临床试验基础上对血红蛋白水平的影响。为此,我们于2024年9月25日通过PubMed、Cochrane和Embase数据库进行了一项检索,以确定缺铁性贫血患者静脉注射铁与输血的比较研究(女性12g /dL,男性13g /dL)。选择的结果是血红蛋白水平的变化。使用Cochrane偏倚风险评估工具和Newcastle-Ottawa质量评估量表评估试验的质量。我们纳入了5项研究(3项随机对照试验、1项观察性研究和1项回顾性研究),共纳入154,539例患者。患者群体具有异质性,包括手术患者、髋部骨折患者和孕妇。由于纳入研究的异质性,血红蛋白水平在不同的随访时间间隔报告。在初始治疗后3周或更晚的随访中,有3项研究报告,与输血组相比,静脉注射铁组的血红蛋白水平明显更高(从0.7 g/dL到1.4 g/dL不等)。其余两项研究发现了相似的血红蛋白水平。初始治疗后不到3周,2项研究报告输血组的血红蛋白水平明显高于静脉注射铁组。我们的研究结果表明,输血在治疗开始后不久实现血红蛋白水平的快速增加更有效,尽管这种效果相对迅速地减弱。相比之下,静脉注射铁似乎对血红蛋白水平的影响更缓慢,但也更持久。然而,我们的发现受到试验数量少以及纳入研究的方法学质量问题的限制,导致高偏倚风险。有必要进一步调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transfusion Medicine Reviews
Transfusion Medicine Reviews 医学-血液学
CiteScore
11.60
自引率
0.00%
发文量
40
审稿时长
21 days
期刊介绍: Transfusion Medicine Reviews provides an international forum in English for the publication of scholarly work devoted to the various sub-disciplines that comprise Transfusion Medicine including hemostasis and thrombosis and cellular therapies. The scope of the journal encompasses basic science, practical aspects, laboratory developments, clinical indications, and adverse effects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信